Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada.
PLoS One. 2012;7(12):e51072. doi: 10.1371/journal.pone.0051072. Epub 2012 Dec 5.
Chemerin is a leukocyte chemoattractant and adipokine with important immune and metabolic roles. Chemerin, secreted in an inactive form prochemerin, undergoes C-terminal proteolytic cleavage to generate active chemerin, a ligand for the chemokine-like receptor-1 (CMKLR1). We previously identified that adipocytes secrete and activate chemerin. Following treatment with the obesity-associated inflammatory mediator TNFα, unknown adipocyte mechanisms are altered resulting in an increased ratio of active to total chemerin production. Based on these findings we hypothesized adipocytes produce proteases capable of modifying chemerin and its ability to activate CMKRL1. 3T3-L1 adipocytes expressed mRNA of immunocyte and fibrinolytic proteases known to activate chemerin in vitro. Following treatment with a general protease inhibitor cocktail (PIC), the TNFα-stimulated increase in apparent active chemerin concentration in adipocyte media was amplified 10-fold, as measured by CMKLR1 activation. When the components of the PIC were investigated individually, aprotinin, a serine protease inhibitor, blocked 90% of the TNFα-associated increase in active chemerin. The serine proteases, elastase and tryptase were elevated in adipocyte media following treatment with TNFα and their targeted neutralization recapitulated the aprotinin-mediated effects. In contrast, bestatin, an aminopeptidase inhibitor, further elevated the TNFα-associated increase in active chemerin. Our results support that adipocytes regulate chemerin by serine protease-mediated activation pathways and aminopeptidase deactivation pathways. Following TNFα treatment, increased elastase and tryptase modify the balance between activation and deactivation, elevating active chemerin concentration in adipocyte media and subsequent CMKLR1 activation.
趋化素是一种白细胞趋化因子和脂肪因子,具有重要的免疫和代谢作用。趋化素以前体蛋白形式(prochemerin)分泌,经 C 端蛋白水解切割后生成活性趋化素,是趋化样受体-1(CMKLR1)的配体。我们之前已经确定脂肪细胞会分泌并激活趋化素。在接受肥胖相关炎症介质 TNFα 处理后,未知的脂肪细胞机制发生改变,导致活性趋化素与总趋化素生成的比例增加。基于这些发现,我们假设脂肪细胞产生能够修饰趋化素及其激活 CMKRL1 能力的蛋白酶。3T3-L1 脂肪细胞表达已知能够在体外激活趋化素的免疫细胞和纤维蛋白溶解蛋白酶的 mRNA。在用广谱蛋白酶抑制剂鸡尾酒(PIC)处理后,TNFα 刺激的脂肪细胞培养基中趋化素的表观活性浓度增加了 10 倍,这可通过 CMKLR1 激活来测量。当单独研究 PIC 的成分时,丝氨酸蛋白酶抑制剂抑肽酶阻断了 90%与 TNFα 相关的活性趋化素增加。在用 TNFα 处理后,脂肪细胞培养基中的弹性蛋白酶和胰蛋白酶水平升高,其靶向中和再现了抑肽酶介导的效应。相比之下,氨基肽酶抑制剂苯丁抑制素进一步增加了与 TNFα 相关的活性趋化素增加。我们的结果支持脂肪细胞通过丝氨酸蛋白酶介导的激活途径和氨基肽酶失活途径来调节趋化素。在 TNFα 处理后,弹性蛋白酶和胰蛋白酶增加会改变激活和失活之间的平衡,从而增加脂肪细胞培养基中活性趋化素的浓度,并随后激活 CMKLR1。